We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+5.69%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.68B
AUM Growth
-$109M
Cap. Flow
-$70.1M
Cap. Flow %
-4.17%
Top 10 Hldgs %
48.34%
Holding
155
New
26
Increased
23
Reduced
13
Closed
37

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$26.4M
2
VTYX
Ventyx Biosciences
VTYX
+$20.8M
3
CBIO
Crescent Biopharma
CBIO
+$19.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$18.3M
5
VRDN icon
Viridian Therapeutics
VRDN
+$16.2M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$30.4M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.4M
3
ONC
BeOne Medicines Ltd
ONC
+$23.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 93.97%
2 Consumer Discretionary 5.18%
3 Financials 0.37%
4 Real Estate 0.31%
5 Technology 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQRX
151
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-2,000,000
Closed -$4.92M
ISEE
152
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,000,000
Closed -$21.4M
BLU
153
DELISTED
BELLUS Health Inc.
BLU
– –
-3,700,000
Closed -$30.4M
APTX
154
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-6,116,493
Closed -$1.75M
CDAK
155
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
– –
-200,000
Closed -$80K
3 4 5 6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2023 Portfolio in Review

As of Q1 2023, Artal Group held 155 positions worth $1.68B, down 6.1% from $1.79B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $70.1M in Q1 2023, closing 37 positions and reducing 13 holdings. Its most notable exit was BELLUS Health Inc., an estimated $30.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Ventyx Biosciences worth $17.9M.

  • Artal Group's largest Q1 2023 buy was Ventyx Biosciences: 535,812 shares worth $17.9M.
  • Artal Group added most to Revolution Medicines in Q1 2023, an estimated $26.4M increase.
  • Artal Group's biggest Q1 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $28.4M.
  • Artal Group fully exited BELLUS Health Inc. in Q1 2023, selling an estimated $30.4M.
  • Artal Group's ten largest holdings make up 48% of its $1.68B portfolio in Q1 2023.
  • Artal Group opened 26 new positions and closed 37 in Q1 2023.
  • Artal Group's portfolio value fell 6.1% quarter-over-quarter to $1.68B.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.